Score Card for Skystar Bio-Pharmaceutical (SKBI)

 Skystar Bio-Pharmaceutical
Shares Outstanding (MRQ): 7.16 mill
Fully diluted shares outstanding (most recent quarter, SEC filing)
POSITIVE: under 30 million shares  |  NEGATIVE: over 50 million shares
New Shares / Dilution (TTM): 0.02 mill0.30%
Newly issued shares in the past 12 months (most recent quarter, SEC filing)
POSITIVE: under 10% dilution  |  NEGATIVE: over 30% dilution
Cash (MRQ): 5.05 mill7,046.30%
Cash and cash equivalents, excl. restricted cash (most recent quarter, SEC filing)
POSITIVE: over 30% of market capitalization  |  NEGATIVE: under 10% of market capitalization
Account Receivables (MRQ): 3.98 mill5,555.86%
Account/Trade receivables (most recent quarter, SEC filing)
POSITIVE: under 10% of market capitalization  |  NEGATIVE: over 30% of market capitalization
Account Receivables (Q/Q): -1.79 mill-31.05%
Quarterly increase/decrease of account/trade receivables (most recent quarter, SEC filing)
POSITIVE: quarterly decrease  |  NEGATIVE: quarterly increase of 20% or more
Relevant only if A/R to market capitalization ration higher than 10%
Long-Term Debt (MRQ): 1.33 mill1,856.40%
Long-term debt excl. warrant liabilities (most recent quarter, SEC filing)
POSITIVE: under 5% of market capitalization  |  NEGATIVE: over 20% of market capitalization
Revenue Growth (Q/Q): 28.35% 
Revenue Growth (Y/Y): 10.06% 
Total revenue growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 30% revenue growth  |  NEGATIVE: negative revenue growth
Net Income Growth (Q/Q): -4.10% 
Net Income Growth (Y/Y): -48.33%
Net income growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 20% net income growth  |  NEGATIVE: negative net income growth
EPS Growth (Y/Y): -48.48%
EPS growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 10% EPS growth  |  NEGATIVE: negative EPS growth
EPS | P/E (2 MRQ Projection): $0.650.02
Projected trailing annual EPS using the two most recently reported quarters
POSITIVE: P/E under 6 / 8 / 10  |  NEGATIVE: P/E over 12
CFPS | P/CF (2 MRQ Projection): -$1.10-0.01
Projected trailing annual Operating Cash Flow per Share using the two most recently reported quarters
POSITIVE: P/CF under 6 / 8 / 10  |  NEGATIVE: P/CF over 12
Price/Sales (2 MRQ Projection): 0.00
Projected trailing annual sales using the two most recently reported quarters
POSITIVE: Price/Sales ratio under 1.25  |  NEGATIVE: Price/Sales ratio over 2.5
Price/Book (MRQ): 0.00
Market capitalization / total stockholders' equity (most recent quarter, SEC filing)
POSITIVE: Price/Book ratio under 1.25  |  NEGATIVE: Price/Book ratio over 2.5
Recent High | Trading near Highs: $3.24-99.70% 
Difference between current price and recent (3-6 months) high
POSITIVE: current price within 20% of recent highs
Recent Low | Trading near Lows: $1.52-99.35%
Difference between current price and recent (3-6 months) low
NEGATIVE: current price within 20% of recent lows
Forward EPS | P/E Projection (Estimates): $0.950.01
Projected forward EPS (Trading China estimates)
POSITIVE: P/E under 4 / 6 / 8  |  NEGATIVE: P/E over 10
Auditor: Crowe Horwath
The Company's independent registered public accounting firm
POSITIVE: Top 10 ranked  |  NEGATIVE: not ranked in the Top 100
SKBI
Agriculture
SCORE
6
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH RISK
DETAILS: Safety/Risk Model for SKBI
Current Price:  $0.01
2008 Close: -99.92%$12.00
2009 Close: -99.91%$10.10
High (2012-02-15): -99.70%$3.24
Low (2012-09-21): -99.35%$1.52
Market Capitalization: 0.07 mill
Last Quarter: 2011-06-30
Revenue (MRQ): 9.10 mill
Net Income (MRQ): 1.15 mill
Op. Cash Flow (MRQ): 2.37 mill
all financial data provided without warranty